Key result
The CardioCoach tool for remote heart failure medication uptitration was feasible and safe, achieving 92.55% medication adherence, with no significant differences found versus usual care.
Why the study?
Does the CardioCoach follow-up tool improve the implementation of guideline recommendations for β-blocker and ACE-I uptitration in heart failure patients?
RCT (n=25)
randomly assigned
Does the CardioCoach follow-up tool improve the implementation of guideline recommendations for β-blocker and ACE-I uptitration in heart failure patients?
A remote monitoring and semiautomatic uptitration tool for heart failure medications is feasible and safe, with high patient adherence, though it requires significant technical support and did not significantly increase guideline-directed medication doses compared to usual care.
Remote HF uptitration tool is feasible and safe with high adherence; leaves open whether it improves guideline-directed dosing versus usual care.
BACKGROUND European Society of Cardiology guidelines for the treatment of heart failure (HF) prescribe uptitration of angiotensin-converting enzyme inhibitors (ACE-I) and β-blockers to the maximum-tolerated, evidence-based dose. Although HF prognosis can drastically improve when correctly implementing these guidelines, studies have shown that they are insufficiently implemented in clinical practice. OBJECTIVE The aim of this study was to verify whether supplementing the usual care with the CardioCoach follow-up tool is feasible and safe, and whether the tool is more efficient in implementing the guideline recommendations for β-blocker and ACE-I. METHODS A total of 25 HF patients were randomly assigned to either the usual care control group (n=10) or CardioCoach intervention group (n=15), and observed for 6 months. The CardioCoach follow-up tool is a two-way communication platform with decision support algorithms for semiautomatic remote medication uptitration. Remote monitoring sensors automatically transmit patient’s blood pressure, heart rate, and weight on a daily basis. RESULTS Patients’ satisfaction and adherence for medication intake (10,018/10,825, 92.55%) and vital sign measurements (4504/4758, 94.66%) were excellent. However, the number of technical issues that arose was large, with 831 phone contacts (median 41, IQR 32-65) in total. The semiautomatic remote uptitration was safe, as there were no adverse events and no false positive uptitration proposals. Although no significant differences were found between both groups, a higher number of patients were on guideline-recommended medication dose in both groups compared with previous reports. CONCLUSIONS The CardioCoach follow-up tool for remote uptitration is feasible and safe and was found to be efficient in facilitating information exchange between care providers, with high patient satisfaction and adherence. CLINICALTRIAL ClinicalTrials.gov NCT03294811; https://clinicaltrials.gov/ct2/show/NCT03294811 (Archived by WebCite at http://www.webcitation.org/6xLiWVsgM)
No takes yet. Share an insight, caveat, or question.
Smeets et al. (2017) conducted an RCT in heart failure (n=25). CardioCoach follow-up tool vs. usual care was evaluated on Feasibility, safety, and efficiency in implementing guideline recommendations for β-blocker and ACE-I. The CardioCoach tool for remote heart failure medication uptitration was feasible and safe, achieving 92.55% medication adherence, with no significant differences found versus usual care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: